Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Ovarian Neoplasms 60Breast Neoplasms 21Neoplasms 19Fallopian Tube Neoplasms 16Prostatic Neoplasms 15Neoplasm Metastasis 9Pancreatic Neoplasms 8Endometrial Neoplasms 8Glioblastoma 7Triple Negative Breast Neoplasms 6Lung Neoplasms 5Carcinoma, Ovarian Epithelial 5Small Cell Lung Carcinoma 4Glioma 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Mesothelioma 3Melanoma 3Head and Neck Neoplasms 3Cystadenocarcinoma, Serous 3Cholangiocarcinoma 3Uterine Neoplasms 2Uterine Cervical Neoplasms 2Urogenital Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Sarcoma 2Prostatic Neoplasms, Castration-Resistant 2Ovarian Diseases 2Mesothelioma, Malignant 2

Interventions

pembrolizumab 287Nivolumab 258Ipilimumab 236aldesleukin 134Cyclophosphamide 134Interleukin-2 104Temozolomide 75Dacarbazine 74trametinib 70Vemurafenib 69fludarabine 67dabrafenib 65fludarabine phosphate 61sargramostim 44binimetinib 44Radiosurgery 44Biopsy 43Paclitaxel 42Bevacizumab 42incomplete Freund's adjuvant 39encorafenib 37Radiotherapy 36Cisplatin 36CTLA-4 Antigen 36atezolizumab 35Carboplatin 35cobimetinib 32Magnetic Resonance Spectroscopy 32Introns 30Specimen Handling 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Melanoma × niraparib × Clear all
NCT05169437 2025-10-29

PAVO

Tempus AI

Phase 2 Terminated
22 enrolled 17 charts
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Breast Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Urologic Neoplasms, Endometrial Neoplasms

NCT03925350 2021-10-22

Efficacy and Safety Study of Niraparib in Melanoma With Genetic Homologous Recombination (HR) Mutation

California Pacific Medical Center Research Institute

Phase 2 Unknown
41 enrolled
Dermatologic

Melanoma

NCT01294735 2012-08-15

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Merck Sharp & Dohme LLC

Phase 1 Completed
19 enrolled
CNSDermatologic

Glioblastoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡